section name header

Pronunciation

ep-ti-FIB-a-tide

Classifications

Therapeutic Classification: antiplatelet agents

Pharmacologic Classification: glycoprotein iib iiia inhibitors

Indications

High Alert


Action

  • Decreases platelet aggregation by reversibly antagonizing the binding of fibrinogen to the glycoprotein IIb/IIIa binding site on platelet surfaces.
Therapeutic effects:
  • Reduction in risk of death or new MI in patients with acute coronary syndrome.
  • Reduction in risk of death, new MI, or need for urgent intervention in patients undergoing PCI.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: 50% excreted by the kidneys.

Half-Life: 2.5 hr.

Time/Action Profile

(effects on platelet function)

ROUTEONSETPEAKDURATION
IVimmediatefollowing bolusbrief



Inhibition is reversible following cessation of infusion.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Noted for patients receiving heparin and aspirin in addition to eptifibatide

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Acute Coronary Syndrome

Percutaneous Coronary Intervention

Renal Impairment

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Integrilin